Double blind, parallel, ramdomised study of two eryaspase formulations in patients with de novo or relapsed acute lymphoblastic leukemia/lymphoma.
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs ERY-ASP (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Pharmacokinetics
- 16 Oct 2017 New trial record
- 08 Sep 2017 According to trial design presented at 42nd European Society for Medical Oncology Congress, recruitment will continue until 38 patients with a PK evaluable profile are enrolled.
- 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.